Cite
Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
MLA
Kongnakorn,Thitima, et al. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1128868927&authtype=sso&custid=ns315887.
APA
Kongnakorn,Thitima, Bharmal,Murtuza, Kearney,Mairead, Phatak,Hemant, Benedict,Agnes, Bhanegaonkar,Abhijeet, & Galsky,Matthew. (2019). Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.
Chicago
Kongnakorn,Thitima, Bharmal,Murtuza, Kearney,Mairead, Phatak,Hemant, Benedict,Agnes, Bhanegaonkar,Abhijeet, and Galsky,Matthew. 2019. “Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1128868927&authtype=sso&custid=ns315887.